aTYR PHARMA annual revenue
2019
2020
2021
2022
2023
2024
2025
aTYR PHARMA Revenue Growth & History (ATYR)
aTYR PHARMA reported $190,000 in revenue for fiscal 2025, a decrease of 19.15% from the previous fiscal year.
View full aTYR PHARMA company overviewaTYR PHARMA annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $190,000 | −$45,000 | −19.15% |
| 2024 | 2024-12-31 | $235,000 | −$118,000 | −33.43% |
| 2023 | 2023-12-31 | $353,000 | −$10.0M | −96.60% |
| 2022 | 2022-12-31 | $10.4M | $10.4M | — |
| 2021 | 2021-12-31 | $0 | −$10.5M | −100.00% |
| 2020 | 2020-12-31 | $10.5M | $10.0M | +2377.49% |
| 2019 | 2019-12-31 | $422,000 | — | — |
aTYR PHARMA quarterly revenue
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $190,000 | $190,000 | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q1 2025 | 2025-03-31 | $0 | −$235,000 | −100.00% |
| Q4 2024 | 2024-12-31 | $0 | $0 | — |
| Q3 2024 | 2024-09-30 | $0 | −$353,000 | −100.00% |
| Q2 2024 | 2024-06-30 | $0 | $0 | — |
| Q1 2024 | 2024-03-31 | $235,000 | $235,000 | — |
| Q4 2023 | 2023-12-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $353,000 | $353,000 | — |
| Q2 2023 | 2023-06-30 | $0 | — | — |
| Q1 2023 | 2023-03-31 | $0 | — | — |
| Q3 2022 | 2022-09-30 | $0 | — | — |
| Q4 2020 | 2020-12-31 | $2.1M | — | — |
| Q3 2020 | 2020-09-30 | $148,000 | −$36,000 | −19.57% |
| Q2 2020 | 2020-06-30 | $189,000 | $95,000 | +101.06% |
| Q1 2020 | 2020-03-31 | $8.1M | — | — |
| Q3 2019 | 2019-09-30 | $184,000 | — | — |
| Q2 2019 | 2019-06-30 | $94,000 | — | — |
aTYR PHARMA revenue growth trends
Over the last five reported fiscal years, revenue declined from $10.5M to $190,000, a compound annual decline of 55.14%. aTYR PHARMA's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review aTYR PHARMA source filings ↗Community posts
aTyr outlines a new Phase 3 sarcoidosis study after FDA discussions
aTyr Pharma ($ATYR) said it had aligned with the FDA on the design of a Phase 3 study of efzofitimod in pulmonary sarcoidosis patients with restrictive lung disease. The planned trial would enroll 372 patients and compare treatment with pla ...
